控释硝苯地平降压效应谷/峰比率的临床研究

中国临床药理学与治疗学 ›› 2001, Vol. 6 ›› Issue (2): 138-141.

控释硝苯地平降压效应谷/峰比率的临床研究

李玉杰, 麦炜颐, 曾群英, 廖晓星, 王礼春, 陈国伟

中山医科大学附属第一医院, 广州 510080

收稿日期:2000-12-01 修回日期:2001-02-14 出版日期:2001-04-26 发布日期:2020-11-25

Clinical study on antihypertensive effect trough to peak ratio of nifedipine GITS

LI Yu-Jie, MAI Wei-Yi, ZENG Qun-Ying, LIAO Xiao-Xing, WANG Li-Chun, Chen Guo-Wei

Department of Cardiology, The First Affiliated Hospital, Sun Yat-Sen University of Medical Sciences, Guangzhou 510080

Received:2000-12-01 Revised:2001-02-14 Online:2001-04-26 Published:2020-11-25

摘要/Abstract

摘要： 目的探讨计算控释硝苯地平治疗原发性高血压患者降压效应谷/峰比率(T/ PR) 的最佳方法和该药的平稳指数(SI)。方法轻、中度原发性高血压患者32 例, 每天早晨服控释硝苯地平(nifedipine GITS) 30 mg, 治疗前及4 w k后作动态血压监测, 分别以2 h个体法和整组法计算T/PR 并计算该药的SI。结果 4 w k治疗后患者偶测血压和动态血压的降低幅度分别为(24 ± 12) / (12 ±8) mmHg和(14.5 ±3.9) /(11.2 ±3.1) mmHg; 个体法计算的收缩压和舒张压的T/PR 分别为0.65 ±0.23 和0.66 ±0.25, 而整组法则分别为0.62和0.68; 该药的收缩压和舒张压SI 分别为3.74和3.77。结论控释硝苯地平可24 h有效平稳地降压;其降压平稳作用可通过T/PR 和SI 反映。

关键词: 高血压, 谷峰比率, 动态血压, 平稳指数, 控释硝苯地平

Abstract: Aim To explore the best way of calculating antihypertensive effect of nifedipine GITS on trough to peak ratio (T/PR), and smoothness index (SI) of the drug from ambulatory blood pressure monitoring (ABPM). Methods 32 cases of mild to moderate essential hypertension patients were enrolled and each was given 30 mg of nifedipine GITS once daily. ABPM was repeated for four weeks. ABPM data were analyzed statistically and T/PR calculated by both individual and whole group way. Results The casual blood pressure (CBP) and ABP were lowered by (24 ±12) / (12 ±8) mmHg and (14.5 ±3.9) / (11.2 ±3.0) mmHg. The T/PR by individual w ay was 0.65 ±0.23 for SBP and 0.66 ±0.25 for DBP, while by whole group way 0.62 for SBP and 0.68 for DBP. The smoothness index (SI), a new method for assessing the homogeneity of 24 hour blood pressure reduction by antihy pertensive therapy, was 3.74 for SBP and 3.77 for DBP after treatment. Conclusion Nifedipine GITS lowers blood pressure effectively and smoothly for 24 hours long. Antihy pertensive effects can be reflected by T/PR and SI.

Key words: hypertension, trough to peak ratio, blood pressure monitoring, ambulatory, smoothness index, nifedipine GITS

中图分类号:

R972.4

李玉杰, 麦炜颐, 曾群英, 廖晓星, 王礼春, 陈国伟. 控释硝苯地平降压效应谷/峰比率的临床研究[J]. 中国临床药理学与治疗学, 2001, 6(2): 138-141.

LI Yu-Jie, MAI Wei-Yi, ZENG Qun-Ying, LIAO Xiao-Xing, WANG Li-Chun, Chen Guo-Wei. Clinical study on antihypertensive effect trough to peak ratio of nifedipine GITS[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2001, 6(2): 138-141.

参考文献

1 Proposed guidelines for the clinical evaluation of antihypertensive drug products(DRAFT) Rockville. Md: Federal Drug Administration Division of Cardio-Renal Drug Products, 1988:4
2 Elliott HL, Meredith PA. Trough peak ratio, clinically useful or practically irrelevant ? J Hypertens, 1995; 13: 279
3 Myers MG.Trough-to-peak ratio and 24hour blood pressure control: methodological issues. Am J Hyper tens, 1995; 8: 214
4 Omboni S, Fogari R, Palatini P, et al. Reproducibility and clinical value of the trough-to-peak ratio of the antihy pertensive effect. Evidence from the sample study. Hypertension, 1998;32:424
5 Mallion JM, Maitre A, de-Galldemaris R, et al. Use of ambulatory blood pressure monitoring in the management of antihy pertensive therapy. Drugs, 1992; 44 (suppl) 1: 12
6 Lipicky RJ. Trough peak ratio: the rationale behind the united states Food and Drug Administration recommendations. J Hypertens, 1994; 12(S8): S17
7 Meredith PA, Ellio tt HL. FDA guidelines on trough: peak ratios in evaluation of antihy pertensive agents. J Cardiovasc Pharmased, 1994; 23(S5): S26
8 Joint National Committee on Prevention, Detection, Evaluation,Treatment of High Blood Pressure. The Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure(JNCVI). Bethesda, Md: national Institutes of Health Publication.1997; 98: 4088
9 Kloner RA, Vetrovec GW, Materson BJ,et al. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. Am J Cardial. 1998; 81: 163
10 Alderman MH, Cohen H, Roque R, et al. Effect of longacting and short -acting calcium antagonists on cardiovascular outcomes in hyper tensive patients. Lancet.1997; 349:594
11 Wurdeman RL, Mooss AN, Mohiuddin SM,et al. Comparison of 24 hour ambula tory blood pressure date in hypertensive patients switched from nifedipine-GITS to nifedipine-CC. Pharmaco therapy. 1999;19:94
12 Parati G, Omboni S, Rizzoni D, et al. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. [J] Hypertens. 1998; 16(11): 1685

[1]	宁思思, 赵玉红, 颜蕾, 唐敏娜, 张凝之, 张泳巧, 崔兆强. 高血压合并慢性肾脏病患者的降压目标之争议[J]. 中国临床药理学与治疗学, 2023, 28(4): 463-467.
[2]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[3]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[4]	张凝之, 赵玉红, 唐敏娜, 张泳巧, 宁思思, 崔兆强. 时辰药理学在高血压治疗中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 418-422.
[5]	崔素梅, 崔兆强. β受体阻滞剂与高血压治疗[J]. 中国临床药理学与治疗学, 2022, 27(4): 423-427.
[6]	李远方, 崔兆强. 高血压合并高尿酸血症的应对之策[J]. 中国临床药理学与治疗学, 2022, 27(4): 428-432.
[7]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[8]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.
[9]	刘桂剑, 程宽, 朱文青, 葛均波. 高血压的药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 446-449.
[10]	邢开, 龚金玉, 罗建权. 噻嗪类利尿剂相关不良反应的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(2): 204-212.
[11]	叶鹏, 谭兴, 冷岳奇, 王杨凯, 王伟忠. 基于交感神经系统的高血压非药物治疗研究现状和进展[J]. 中国临床药理学与治疗学, 2021, 26(12): 1335-1343.
[12]	谢祥妹，黄志红，刘小菊，薛冰，蓝保珠. 叶酸片联合阿托伐他汀治疗对H型高血压患者同型半胱氨酸及颈动脉粥样硬化的影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 455-459.
[13]	崔海鞠, 马张庆, 杨魁, 汪五三, 许慧芳, 栾家杰. 褪黑素在非杓型自发性高血压大鼠体内的时辰药动学研究[J]. 中国临床药理学与治疗学, 2020, 25(12): 1337-1343.
[14]	印清, 杜荣增. 机械敏感性离子通道Piezo1在心血管疾病中的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(12): 1414-1421.
[15]	张俊秀, 沈媛媛, 杨解人, 郑书国, 郝伟. 联用芝麻素和维生素E抑制PI3K/AKT信号通路改善自发性高血压大鼠的左室纤维化[J]. 中国临床药理学与治疗学, 2020, 25(11): 1214-1222.